BRUKER CORP
BRKRNASDAQTrading Snapshot
- Day Range
- $56.75 – $57.27
- 52-Week Range
- $28.53 – $65.30
- Volume
- $2.33B
- Avg Volume
- $3.01B
- Shares Outstanding
- 152.2M
- Next Earnings
- Oct 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $3.44B
- Last Q Revenue
- $839M
- P/E Ratio
- —
- P/S Ratio
- 2.4x
- EPS (TTM)
- $-0.47
- Dividend Yield
- 0.64%
Why Investors Own BRKR
- ✓High-growth profile — revenue up +41.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 73% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BRUKER CORP
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development
LEIDEN, The Netherlands, August 10, 2026--Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker’s post-genomic solutions for disease biology research, as well as for drug discovery and development into Microphysiological Systems (MPS), also referred to as New Approach Methodologies (NAMs), and based on human phy
Is Bruker (BRKR) Fairly Valued After Its 52 Week High?
Bruker stock has had a strong run over the past year while the latest valuation work, including a Discounted Cash Flow (DCF) intrinsic value estimate and market multiple checks, still points to the shares trading at a discount to those fundamentals. Bruker has returned 57.6% over the past year, which puts extra focus on whether that share price move is now in line with the company’s underlying value. Recent acquisitions in life sciences, including the DISQVER metagenomic sequencing platform,...
Carillon Chartwell Mid Cap Value Fund Q2 2026 Portfolio Review
ON Semiconductor designs and manufactures power and sensing semiconductors for automotive, industrial, and data center applications.
Citigroup Maintains Neutral on Bruker, Lowers Price Target to $53
Citigroup analyst Brendan Digan maintains Bruker (NASDAQ:BRKR) with a Neutral and lowers the price target from $60 to $53.
Weak Growth In Its Primary Market Continues To Weigh Heavily On Bruker Shares
Bruker Corporation faces ongoing headwinds from weak academic/government funding that has compressed growth. Read more on BRKR stock here.
Bruker (BRKR) Is Down 20.0% After Goodwill Impairment-Fueled Q2 Loss Despite Higher Sales
Bruker Corporation’s Q2 2026 results, released on August 4, 2026, showed sales rising to US$838.5 million from US$797.4 million year over year, but a goodwill and intangible asset impairment charge of US$134.9 million and other items drove a net loss of US$52 million versus prior-year net income. The company reaffirmed a path to growth by guiding Fiscal Year 2026 revenues to US$3.54–US$3.57 billion, implying 3%–4% reported growth over 2025, while targeting cost savings and maintaining its...